| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 196.6MM | +2% |
| Operating Income | -31.4MM | -48% |
| Operating Expenses | 228MM | - |
| Net Income | -31.2MM | -49% |
| R&D | 21MM | -12% |
| G&A | 144.4MM | +6% |
| Amortization | 10.8MM | +1% |
| Interest Expense | 900K | -10% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Management will also participate in four upcoming investor healthcare conferencesSALT LAKE CITY, April 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on Tuesday, May 7, 2024 at 4:30pm ET. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the com
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
80% of people diagnosed with anxiety, depression report losing years or decades of timeSALT LAKE CITY, April 17, 2024 (GLOBE NEWSWIRE) -- An astonishing 44% of Americans feel they have lost time in their lives due to poor mental health. That number jumps to nearly 80% for those diagnosed with anxiety and/or depression, according to the latest GeneSight Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine. Of those
SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Prenatal Diagnosis has published a study1 demonstrating exceptional positive predictive value (PPV) for 22q11.2 microdeletion screening using Myriad’s prenatal cell-free DNA (pcfDNA) screen, Prequel®, which incorporates fetal fraction amplification. Prior studies from other commercial pcfDNA laboratories have reported a broad range of
Myriad Genetics' (MYGN) latest positive initial study outcome is likely to improve clinical outcomes and reduce overall healthcare costs.
Investors are optimistic about Myriad Genetics' (MYGN) strong solvency position and improvement in testing volume.
Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight testSALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight® Psychotropic test. “We are encouraged by the initial results of
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Myriad Genetics' (MYGN) new patent grant is likely to bolster the ability to deliver a tumor-informed, high-definition MRD assay to the market.